By Colin Kellaher
Eli Lilly said an experimental drug nearly eliminated an inherited type of bad cholesterol at its highest dose in a mid-stage study.
Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein(a), or lp(a), met its primary endpoint, reducing lp(a) levels by an average of 93.9% over the 60- to 180-day period after treatment with the highest tested dose of 400 milligrams.
The Indianapolis drugmaker said study participants who received the 16-milligram and 96-milligram lepodisiran doses saw reductions of 40.8% and 75.2% in lp(a) levels, respectively.
About 20% of Americans have high levels of lp(a), which is genetic and has been linked to increased risk for heart attack, stroke and other cardiovascular diseases. There are currently no FDA-approved drugs to lower lp(a) levels.
Eli Lilly said it will continue to evaluate the potential benefits of lepodisiran in an ongoing Phase 3 study.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 31, 2025 06:56 ET (10:56 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。